Rich Market Daily
Advertisement
  • Investing
  • Economy
  • Stocks
  • Business
No Result
View All Result
  • Investing
  • Economy
  • Stocks
  • Business
No Result
View All Result
Rich Market Daily
No Result
View All Result
Home Business

FDA officially authorizes Zyn nicotine pouches for sale following health review

admin by admin
January 18, 2025
in Business
0
FDA officially authorizes Zyn nicotine pouches for sale following health review
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

The U.S. Food and Drug Administration formally authorized Zyn nicotine pouches for sale after conducting an ‘extensive scientific review’ about their safety.

In a release Thursday, the agency said it had found that the popular pouches posed lower risk of cancer and other serious health conditions compared with cigarettes, as well as in relation to other smokeless tobacco products.

The agency also found that the pouches even had the potential to benefit cigarette smokers amid evidence that they can get them to quit.

‘The data show that these nicotine pouch products meet that bar by benefiting adults who use cigarettes and/or smokeless tobacco products and completely switch to these products,” Matthew Farrelly, director of the office of science in the FDA’s Center for Tobacco Products, said in a statement. 

Zyn use has exploded in recent years in the wake of a viral online meme trend, even prompting a shortage last year. Yet the product had been operating in a legal gray area while it underwent official FDA review about its health effects and uptake among young users.

To that latter point, the FDA found that, so far, Zyn use among youths appeared to be relatively low, though it was continuing to monitor the trend.

A spokesperson for Philip Morris International Inc., which owns the U.S. rights to Zyn, did not immediately respond to a request for comment.

Swedish Match, the developer of Zyn, said in a statement, “The FDA’s authorization of all ZYN nicotine pouches currently marketed by Swedish Match in the U.S. is an important step to protect the public health by providing better alternatives to cigarettes and other traditional tobacco products for adults 21+.”

The Campaign for Tobacco-Free Kids slammed the FDA’s decision in a separate statement.

‘The FDA today has set a dangerous precedent that puts the nation’s kids at risk by authorizing the sale of 20 Zyn nicotine pouch products with flavors that clearly appeal to kids, including chill, citrus, cool mint and peppermint,’ it said.

‘The FDA’s decision is deeply troubling given the extensive scientific evidence that flavored tobacco products appeal to kids and the fact that nicotine pouches were the only category of tobacco product that saw an increase in youth use last year. The FDA is sanctioning a flavored tobacco product that is already increasing in popularity with kids and repeating the mistakes it made with Juul that resulted in the youth e-cigarette epidemic.’

In the release, the FDA emphasized that its findings about Zyn did not mean the products are ultimately safe or “FDA approved.”

‘There is no safe tobacco product,’ the agency said. ‘Youth should not use tobacco products and adults who do not use tobacco products should not start.’

This post appeared first on NBC NEWS

Previous Post

Vanadium Market Forecast: Top Trends for Vanadium in 2025

Next Post

S&P 500 climbed 0.3%, and Nasdaq-100 futures jumped 0.7%

admin

admin

Next Post
S&P 500 climbed 0.3%, and Nasdaq-100 futures  jumped 0.7%

S&P 500 climbed 0.3%, and Nasdaq-100 futures jumped 0.7%

Recent News

Victoria Gold-Silver Exploration Update

Victoria Gold-Silver Exploration Update

June 5, 2025
Scoping Study Demonstrates Low Cost Potential (Replacement)

Scoping Study Demonstrates Low Cost Potential (Replacement)

June 5, 2025
Why ADX Can Mislead You — And How to Avoid It

Why ADX Can Mislead You — And How to Avoid It

June 5, 2025
S&P 500 on the Verge of 6,000: What’s at Stake?

S&P 500 on the Verge of 6,000: What’s at Stake?

June 5, 2025
Disclaimer: richmarketdaily.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.
  • About us
  • Contact us
  • Privacy Policy
  • Terms & Conditions

Copyright © 2025 richmarketdaily.com | All Rights Reserved

No Result
View All Result
  • About us
  • Contact us
  • Home 1
  • Home 2
  • Home 3
  • Home 4
  • Home 5
  • Home 6
  • Privacy Policy
  • Terms & Conditions
  • Thank you

Copyright © 2025 richmarketdaily.com | All Rights Reserved